NAGIOS: RODERIC FUNCIONANDO

Rationale for combined therapies in severe-to-critical COVID-19 patients

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Rationale for combined therapies in severe-to-critical COVID-19 patients

dc.contributor.author	Gonzaga Moltó, Aitor
dc.contributor.author	Andreu Sánchez, Etelvina
dc.contributor.author	Hernández-Blasco, Luis Manuel
dc.contributor.author	Meseguer, Rut
dc.contributor.author	Al-Akioui-Sanz, Karima
dc.contributor.author	Soria Juan, Bárbara
dc.contributor.author	Sanjuan Gimenez, Jose Carlos
dc.contributor.author	Ferreras, Cristina
dc.contributor.author	Tejedo, Juan R.
dc.contributor.author	Lopez Lluch, Guillermo
dc.contributor.author	Goterris Viciedo, Rosa
dc.contributor.author	Maciá Soler, Loreto
dc.contributor.author	Sempere Ortells, José Miguel
dc.contributor.author	Hmadcha, Abdelkrim
dc.contributor.author	Borobia Pérez, Alberto
dc.contributor.author	Vicario, Jose L.
dc.contributor.author	Bonora, Ana
dc.contributor.author	Aguilar, Cristóbal
dc.contributor.author	Poveda Andrés, José Luis
dc.contributor.author	Arbona, Cristina
dc.contributor.author	Alenda González, Cristina
dc.contributor.author	Tarin Rodrigo, Fabián
dc.contributor.author	Marco, Francisco M.
dc.contributor.author	Merino de Lucas, Esperanza
dc.contributor.author	Jaime Sánchez, Francisco Ángel
dc.contributor.author	Ferreres, José
dc.contributor.author	Figueira Iglesias, Juan Carlos
dc.contributor.author	Cañada Illana, Carlos
dc.contributor.author	Querol Giner, Sergio
dc.contributor.author	Guerreiro, Manuel
dc.contributor.author	Eguizabal, CristinaC
dc.contributor.author	Martín Quirós, Alejandro
dc.contributor.author	Robles Marhuenda, Ángel
dc.contributor.author	Pérez Martínez, Antonio
dc.contributor.author	Solano Vercet, Carlos
dc.contributor.author	Soria, Bernat
dc.date.accessioned	2023-10-16T15:57:46Z
dc.date.available	2023-10-16T15:57:46Z
dc.date.issued	2023
dc.identifier.citation	Gonzaga Moltó, Aitor Andreu Sánchez, Etelvina Hernández-Blasco, Luis Manuel Meseguer, Rut Al-Akioui-Sanz, Karima Soria Juan, Bárbara Sanjuan Gimenez, Jose Carlos Ferreras, Cristina Tejedo, Juan R. Lopez Lluch, Guillermo Goterris Viciedo, Rosa Maciá Soler, Loreto Sempere Ortells, José Miguel Hmadcha, Abdelkrim Borobia Pérez, Alberto Vicario, Jose L. Bonora, Ana Aguilar, Cristóbal Poveda Andrés, José Luis Arbona, Cristina Alenda González, Cristina Tarin Rodrigo, Fabián Marco, Francisco M. Merino de Lucas, Esperanza Jaime Sánchez, Francisco Ángel Ferreres, José Figueira Iglesias, Juan Carlos Cañada Illana, Carlos Querol Giner, Sergio Guerreiro, Manuel Eguizabal, CristinaC Martín Quirós, Alejandro Robles Marhuenda, Ángel Pérez Martínez, Antonio Solano Vercet, Carlos Soria, Bernat 2023 Rationale for combined therapies in severe-to-critical COVID-19 patients Frontiers in Immunology 14
dc.identifier.uri	https://hdl.handle.net/10550/90371
dc.description.abstract	An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19's pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.
dc.relation.ispartof	Frontiers in Immunology, 2023, vol. 14
dc.subject	Virus
dc.subject	Malalties
dc.title	Rationale for combined therapies in severe-to-critical COVID-19 patients
dc.type	journal article
dc.date.updated	2023-10-16T15:57:47Z
dc.identifier.doi	10.3389/fimmu.2023.1232472
dc.identifier.idgrec	161468
dc.rights.accessRights	open access